EPCAM+, EPCAM− and EPCAM−Rhoj-KO tumour cells similarly increased the level of phosphorylated ATM/ATR substrates after cisplatin/5FU administration (Fig. 4a), showing that RHOJ does not control ATM and ATR activation after chemotherapy. Here, RHOJ is linked to neoplasm.